Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

被引：4

作者：

Chen, Ning ^{[2
,3
]}

Xu, Xiaoling ^{[1
]}

Fan, Yun ^{[1
]}

机构：

[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China

[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China

[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, Hangzhou, Zhejiang, Peoples R China

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷

基金：

中国国家自然科学基金;

关键词：

biomarker; immune checkpoint inhibitor; immunotherapy; oesophageal squamous cell carcinoma; PD-L1; OPEN-LABEL; TUMOR MICROENVIRONMENT; POOR-PROGNOSIS; PHASE-II; CANCER; NIVOLUMAB; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAMRELIZUMAB; EXPRESSION;

D O I：

10.1177/17588359231189420

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.

引用

页数：18

共 50 条

[41] Where We Were and Where We Are Going
Brown, Helene
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (06) : 555 - 556
[42] WHERE WE ARE, AND WHERE WE ARE GOING - WRONG
SCHIOLDANNNIELSEN, J
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 1988, 22 (04): : 349 - 350
[43] Neoadjuvant treatment of rectal cancer: Where we are and where we are going
Del Portillo, Elisabet Gonzalez
Counago, Felipe
Lopez-Campos, Fernando
WORLD JOURNAL OF CLINICAL ONCOLOGY, 2024, 15 (07):
[44] Where we are and where we're going
Falcioni, JG
MECHANICAL ENGINEERING, 2005, 127 (04) : 4 - 4
[45] NUTRITION - WHERE ARE WE . WHERE ARE WE GOING
HARPER, AE
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1969, 22 (01): : 87 - &
[46] STEREOLOGICAL METHODS IN CELL BIOLOGY - WHERE ARE WE - WHERE ARE WE GOING
WEIBEL, ER
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (09) : 1043 - 1052
[47] Single-cell metabolomics: where are we and where are we going?
Lanekoff, Ingela
Sharma, Varun V.
Marques, Catia
CURRENT OPINION IN BIOTECHNOLOGY, 2022, 75
[48] Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Tovoli, Francesco
De Lorenzo, Stefania
Trevisani, Franco
VACCINES, 2020, 8 (04) : 1 - 21
[49] 'WHERE ARE WE, WHERE HAVE WE COME FROM, WHERE ARE WE GOING'
BOLTON, K
OVERLAND, 1991, (123): : 52 - 53
[50] WHERE WERE WE, WHERE ARE WE, WHERE ARE WE GOING, AND WHO CARES
WOOLSEY, G
INTERFACES, 1993, 23 (05) : 40 - 46

← 1 2 3 4 5 →